Patheon, a DPx Holdings B.V. business unit, is the leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including small molecule API and biologic drug substances.
DPx Holdings’ global manufacturing network, which spans its three business units, Patheon, DPx Fine Chemicals and Banner Life Sciences, includes more than 8,000 employees providing services at 12 commercial-scale finished dose form facilities, three API manufacturing and development operations,
four biologic drug operations, one biosolution facility and nine pharmaceutical development centers commercial contract manufacturing facilities across North America, Europe, Asia and Australia.
The company enables its customers to bring drug candidates from preclinical stages through to clinical trials, the NDA approval process and, if approved, commercial manufacturing. Patheon's development and commercial manufacturing capabilities cover primarily prescription (Rx) products in solid and sterile dosage forms, as well as specialized capabilities in high potency, controlled/sustained release, and sterile manufacturing, including aseptic filling and lyophilization.
Patheon’s key capabilities for biologics include flexible, technology-based process development, clinical and commercial cGMP manufacturing for mammalian cell culture derived biopharmaceuticals and chemical bulk drug substances. Patheon can serve early, late and commercial stage markets providing end-to-end solutions to customers through its four biologics sites in the U.S., Europe and Australia.
The pharmaceutical industry is growing and, compared with other industries, is in the early stages of adopting manufacturing and development outsourcing strategies. Many global pharma, biotech and specialty pharma companies rely on the services of contract product development and commercial manufacturing companies to help meet growing demand and bring new drugs to market more quickly.
Patheon is the established leader in this relatively new segment of the pharmaceutical industry. With a wide range of manufacturing capabilities and significant scale in the world's two largest pharmaceutical markets – the United States and Europe – the company is uniquely positioned to serve as a strategic global manufacturing partner to the industry's leading innovators.
Patheon serves approximately 300 clients, including 19 of the 20 largest pharmaceutical companies, seven of the top 10 biotech companies, and seven of the 10 largest specialty pharmaceutical companies.